Lianhua Qingwen sold 2 billion yuan in half a year, but the dilemma of Chinese medicine going abroad is still difficult to break

Half a year to sell 2 billion lianhua Qing plague to borrow out to sea? After the outbreak of new coronary pneumonia, Lianhua Qing plague capsules/particles were listed as recommended for use in the "Pneumonia Diagnosis and Treatment Program for New Coronavirus Infections" (trial 4/5/6/7/8) jointly issued by the National Health And Health Commission and the State Administration of Traditional Chinese Medicine.
April this year, the State Drug Administration approved Lianhua Qing plague capsules/particles to add "new coronavirus pneumonia light, common type" of new adaptation on the basis of the original approved adaptation.
, Ering Pharmaceuticals released its first half 2020 sales results.
as the leading product of Ling Pharmaceuticals, Lianhua Qing plague achieved operating income of 1.703 billion yuan in 2019, accounting for 29.24% of the company's total operating income.
In the first half of 2020, Lianhua Qing plague products achieved operating income of 2,024 million yuan, accounting for 45.11% of the company's total operating income, an increase of 50.35% over the same period last year, becoming the absolute main force of first-half revenue of Ering Pharmaceuticals.
first half of this year, Lianhua Qing plague product sales revenue achieved rapid growth compared to the same period last year, especially in the second quarter of a single quarter year-on-year growth of nearly 500%.
the second quarter of last year was the off-season, but this year's off-season is not light.
Lianhua Qing plague as an anti-epidemic star visibility has been greatly improved, the second quarter of the domestic epidemic has been well controlled, but still due to the resumption of work and return to work and as a 'cure cold anti-flu' demand and other factors, Lianhua Qing plague sales year-on-year still achieved better results, to a certain extent reflects Lianhua Qing plague in the traditional influenza and cold market share has been greatly improved.
" Ering Pharmaceuticals said in a record of investor relations activity on August 29.
data show that Lianhua Qing plague capsules in the first quarter of 2020 OTC terminal in the sales of chinese medicine cold drugs ranked No. 1, accounting for about 10% of the market share.
fact, even the flower clear plague capsule's way out to sea is not smooth.
chinese medicine, which has played an important role in the domestic anti-epidemic process, overseas demand and attention are also increasing, bringing opportunities for Chinese medicine products to go abroad and go to the world.
Taking Lianhua Qing Plague as an example, according to Ling Pharmaceutical Announcement, Lianhua Qing Plague Capsules have been registered as "Traditional Chinese Medicine", "Pharmaceuticals", "Plant Medicine", "Natural Health Products", "Food Supplements", "Modern Plant Medicine" and "Natural Medicine" in Hong Kong, Macao and Brazil, Indonesia, Canada, Mozambique, Romania, Thailand, Ecuador, Singapore, Laos, Kyrgyzstan, Philippines, Kuwait, Mauritius and Uganda respectively.
It is worth noting that Lianhua Qing plague capsules in Kuwait's market approval includes the new coronary pneumonia-related adaptation, which is also the first time Lianhua Qing plague capsules have been approved in overseas countries for the treatment of light and common type of new coronavirus pneumonia-related symptoms.
even flower clear plague capsules have been registered in many countries listed, but sales abroad has not yet formed a scale.
is subject to the access system, cultural differences and other factors, Toling Pharmaceuticals' current overseas sales revenue as a proportion of the company's total operating income is still low.
to expand overseas business, Ling Pharmaceuticals has set up an ITC, fully responsible for the overseas market sales of products.
at the same time, also in the Middle East, Africa, Latin America and other countries to actively promote the registration work, continue to actively promote the overseas registration and sales of Lianhua Qing plague products, in order to further expand the overseas market share of products to make positive efforts.
Chinese medicine out to sea in trouble also need to establish a standardized evaluation system Although the growing overseas epidemic to a certain extent to promote the promotion of Chinese medicine, for Chinese medicine to open up overseas markets to create a new opportunity, but the medical profession generally believes that the current Chinese medicine out to sea is still difficult, want to enter overseas hospitals is not easy.
drug concept, laws and regulations, cultural differences, etc. have become Chinese medicine to land at sea must go through several bumps.
, Chinese medicine exports have remained in the billions of dollars in recent years, while chemical agent exports have exceeded 10 billion U.S. dollars.
the huge disparity in the amount reflects the real difficulties of Chinese medicine going to sea.
in the western mainstream pharmaceutical market, Chinese medicine as a drug registration in the United States has not yet achieved zero breakthrough, in the European Union can successfully register a few.
the current overseas sales target customers are still mainly Chinese, products are also concentrated in medicinal herbs or drink tablets, chinese traditional medicine is mostly through assistance and other channels to enter the European and American markets.
a long time, Chinese medicine "cannot be said, the road is not clear, do not understand", greatly affected its international promotion, and even can only be placed on the shelves of health care products or food additives, can not obtain the identity of drugs.
the influence of cultural differences in the inherent concepts, the way of Chinese medicine to the sea is also restricted by laws and regulations between different countries.
Taking the EU market as an example, in 2004 the EU issued the Traditional Plant Medicine Registration Procedure Directive, which requires all plant medicines sold in the EU market to be registered in accordance with the new regulations and licensed for listing before they can continue to be sold as herbs.
Industry experts said, "Just as China has specific drug entry systems and regulations, so do overseas countries, but because the standards vary from country to country, and chinese medicine theory and scientific experiments are more difficult, it is difficult to pass the identification of other countries."
, such as the popular Kawabe paste in 2018, has not received approval for the drug in the United States.
industry, one of the keys to the chinese medicine's troubles lies in the lack of uniform scientific standards that can be accepted by Western countries.
And Western medicine is different, Chinese medicine is mostly compound, complex composition, the mechanism of action is often the result of the synergy of several flavor drugs, its specific active ingredients and mechanism of action is not clear, poor control, which is difficult to verify the specific standards of Chinese medicine, but also the reason why Chinese medicine is difficult to pass foreign drug approval.
because of this, Chinese medicine is not adapted to the Western modern new drug research and development evaluation system, it is difficult to obtain a drug as a pass to enter the country or regional hospitals.
addition, Chinese medicine exports have been returned due to substandard quality and even pesticide residues.
industry experts in recent years have repeatedly called for domestic pharmaceutical companies to comply with international plant medicine production norms, which is responsible for the production system of enterprises and even Chinese medicine brands.
Chinese medicine to go out to sea also need their own hard, Chinese medicine products should ensure the whole process of systematic norms, in strict accordance with quality standards to grow, production, in order to be expected to stand in overseas markets.
analysts pointed out that after the outbreak, overseas enthusiasm for Chinese medicine can continue, the road to the market of Chinese medicine can relax a trace is not yet known.
but it is certain that Chinese medicine still has a long way to go in the race for international voice.
.